The state of radiological protection; views of the radiation protection profession: IRPA13, Glasgow, May 2012.

The IRPA13 Congress took place from 14-18 May 2012 in Glasgow, Scotland, UK, and was attended by almost 1500 radiological protection professionals. The scientific programme of the Congress was designed to capture a snapshot of the profession's views of the current state of knowledge, and of the challenges seen for the coming years. This paper provides a summary of these results of the Congress in twelve key scientific areas that served as the structural backbone of IRPA13.

Implementation and validation of portal dosimetry with an amorphous silicon EPID in the energy range from 6 to 25 MV.

The purpose of this study was to develop, implement and validate a method for portal dosimetry with an amorphous silicon EPID for a wide energy range. Analytic functions were applied in order to correct for nonlinearities in detector response with dose rate, irradiation time and total dose. EPID scattering processes were corrected for by means of empirically determined convolution kernels.

Dose-response characteristics of an amorphous silicon EPID.

Electronic portal imaging devices (EPIDs) were originally developed for the purpose of patient setup verification. Nowadays, they are increasingly used as dosimeters (e.g.

Estimation of doses to personnel and patients during endovascular brachytherapy applications.

In the last few years coronary endovascular brachytherapy using gamma- and beta-emitting radionuclides has been established as a standard treatment procedure to prevent restenosis after percutaneous coronary interventions. Direct measurements and calculations were made to determine personnel doses and organ doses of patients due to gamma rays of 192Ir and beta rays of 90Sr/90Y and 32P sources. In general, our results show that the dose levels are low compared with the X-ray exposure from angiography.